BUZZ-Shire Plc: Agrees with FDA on regulatory path for ADHD drug

** British drugmaker's U.S.-listed shares up about 3 pct at $236.41 premarket

** Says it agreed with U.S. FDA on steps it would take to submit its experimental drug to treat hyperactivity disorder in adults for approval

** Says it anticipates launching the drug, SHP465, in the second half of 2017

** Agrees to conduct short-term efficacy and safety study in pediatric patients with attention deficit hyperactivity disorder (ADHD) in the event of use in this population

** Up to Monday's close, stock had risen 8 pct this year